EMERGENT BIOSOLUTIONS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
EMERGENT BIOSOLUTIONS INC. (EBS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 800.00 thousand shares for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-12-11.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2023-12-11
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-09-30 was 100.00K shares.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-06-30 was 400.00K shares.
- EMERGENT BIOSOLUTIONS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-03-31 was 300.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month |
|---|---|---|---|
| 2023-09-30 | 100.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-11 | 500.00K shares derived: sum of 2 quarters · filed 2023-12-11 | 800.00K shares 10-Q · filed 2023-12-11 |
| 2023-06-30 | 400.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 700.00K shares 10-Q · filed 2023-08-09 | |
| 2023-03-31 | 300.00K shares 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |